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Abstract
The mechanism of action of DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-aza-CdR), a potential anticancer
agent is believed to be activated by the demethylation of tumor suppressor genes. We tested here the hypothesis
that demethylating agents also demethylate and activate genes involved in invasion and metastasis and therefore
might increase the risk of developing tumor metastasis. The effect of 5-aza-CdR on noninvasive human breast cancer
cells MCF-7 and ZR-75-1 was evaluated by cell proliferation, invasion, and migration assay. The ability of 5-aza-CdR to
activate a panel of silenced prometastatic and tumor suppressor genes was evaluated using reverse transcription–
polymerase chain reaction and bisulfite DNA sequence analysis in vitro and for change in tumor growth and gene
expression in vivo. Treatment of MCF-7 and ZR-75-1 with 5-aza-CdR diminished cell proliferation, induced tumor
suppressor RASSF1A, and altered cell cycle kinetics’ G2/M–phase cell cycle arrest. While these effects of 5-aza-
CdR slowed the growth of tumors in nude mice, it also induced a battery of prometastatic genes, namely, uPA,
CXCR4, HEPARANASE, SYNUCLEIN γ, and transforming growth factor-beta (TGF-β), by demethylation of their pro-
moters. These results draw attention to the critical role of demethylation as a potential mechanism that can promote
the development and progression of tumor metastasis after demethylation therapy as an anticancer treatment.
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Introduction
Hypermethylation of tumor suppressor genes is a common mechanism
of gene silencing observed in cancer [1]. Knock down of DNA methyl-
transferase 1, the enzyme that is involved in the copying of DNA
methylation during cell division, by either pharmacological [2,3] or
genetic approaches [4], was shown to inhibit cancer in animal mod-
els. The DNA methyltransferase inhibitor, 5-aza-2′-deoxcytidine
(5-aza-CdR), was shown to demethylate and induce the activity of
methylated tumor suppressor genes [5]. 5-Aza-CdR is currently being
tested in different clinical trials as an anticancer agent [6–8]. Breast
cancer is the most common malignant disease affecting women of
all age group globally; during this multistep process of tumor pro-
gression, the disease was initiated as a less-aggressive nonmetastatic
hormone-responsive–type, which gradually develop as a highly invasive
and metastatic hormone-insensitive malignancy. Most of the mortal-
ities among these patients are due to delayed diagnosis, poor prognosis,
and metastases to the distant organs especially lung and bones, which
are more frequent sites of breast cancer metastases [9]. The early steps
of the metastatic cascade involving the degradation of the extracellular
matrix and subsequent invasion by cancer cells are accomplished by sev-
eral proteinases, including among others, urokinase-type plasminogen
activator (uPA), heparanase and matrix metalloproteinase (MMPs),
and other proteins, by which different lines of data suggest to contrib-
ute to metastasis, such as transforming growth factor-beta (TGF-β),
S100A4, SYNUCLEIN γ, and CXCR4 [10–20]. We have previously
shown that uPA promoter region is hypomethylated, and its expression
is upregulated in the invasive breast cancer cell line MDA-MB-231
(hormone insensitive), whereas the same promoter region is methylated
in noninvasive breast cancer cells such as MCF-7 (hormone-responsive).
Furthermore, 5-aza-CdR treatment induces the expression of uPA in
noninvasive MCF-7 cells [21]. Similar effects were also observed in
a hormone-responsive human prostate cancer cell line, LNCaP, after
the treatment with 5-aza-CdR [22]. We have also shown that reverting
the hypomethylated status of uPA promoter in MDA-MB-231 cells by
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either S-adenosyl-L-methionine treatment or knock down of methyl
DNA binding domain protein 2 causes significant inhibition in uPA
expression and invasion in vitro and tumor growth in vivo [23]. We
previously hypothesized that reactivation of expression of prometastatic
genes by DNA demethylation is a common contributing factor to pro-
moting tumor metastasis [24]. Therefore, we suggested that although
inhibition of DNA methylation results in decreasing tumor growth
by the activation of tumor suppressor genes, it might, at the same time,
result in the activation of prometastatic genes, suggesting divergence of
growth control and invasion in breast cancer cells [24,25].
In the present study, we tested this hypothesis by examining the
effects of 5-aza-CdR, a classic DNA methylation inhibitor, which is
currently tested in clinical trials, on the expression and DNA meth-
ylation of the tumor suppressor gene, RASSF1A, and a set of genes
involved in metastasis/angiogenesis of breast cancer, such as uPA,
HEPARANASE, CXCR4 RECEPTOR, STROMAL CELL–DERIVED
FACTOR 1α (CXCL12), BREAST CANCER–SPECIFIC GENE 1 or
SYNUCLEIN γ (SNCG ), VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF ), and TGF-β as well as genes involved in cell cycle,
such as cyclin-dependent kinase inhibitors ( p21WAF1/Cip1, CYCLIN
D1, and CYCLIN E1) and BAX, a proapoptotic gene of the Bcl-2
family [10,11,14,15,17,26–34]. We then tested whether 5-aza-CdR
will convert nonmetastatic breast cancer cell lines MCF-7 and ZR-
75-1 to invasive and metastatic cells using in vitro and in vivo assays.
Our data support a mechanism for the potential capacity of 5-aza-CdR
to induce the expression of previously quiescent prometastatic genes
and for the need to carefully evaluate and monitor patients receiving
DNA methylation inhibitors.
Materials and Methods
Cell Culture and Treatment
Human breast cancer cell line, MCF-7 and ZR-75-1 cells were ob-
tained from the American Type Culture Collection (Manassas, VA).
MCF-7 cells were maintained in minimum Eagle’s medium (Earle’s
salts; Invitrogen Life Technologies, Ontario, Canada) with 2 mM
L-glutamine, 10% FBS, 10 μg/ml insulin, and 100 U/ml of penicillin-
streptomycin sulfate. ZR-75-1 cells were grown in RPMI 1640 medium
(Invitrogen Life Technologies) with 10% FBS, 2 mM L-glutamine ad-
justed to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM
HEPES, and 1.0 mM sodium pyruvate. Cells were incubated at 37°C
in 5% CO2. In the 5-aza-CdR treatment group, MCF-7 and ZR-75-1
cells were treated for 7 days with 5-aza-CdR (Sigma Aldrich, Ontario,
Canada) at final concentrations of 0.1, 1, and 5 μM in the regular me-
dium. The culture medium was changed every second day in both con-
trol and treatment groups by maintaining the desired concentration of
the drug.
Cell Proliferation Assay
MCF-7 and ZR-75-1 cells were plated in quadruplicate at a den-
sity of 50,000 cells/well in 2 ml of respective culture media in six-
well plates. Cells were grown in the regular medium with 5% FBS in
the control and treatment (5-aza-CdR) groups. Cell growth curve
was analyzed at two different doses of 5-aza-CdR (1 and 5 μM). Cells
were trypsinized, and the number of viable cells was determined
by 0.4% trypan blue and counted at different time points starting
from day 0 (without 5-aza-CdR) using a Coulter counter (Model
ZF; Coulter Electronics, Hertfordshire, UK). Cell culture medium
was replenished every second day along with the indicated dose of
5-aza-CdR in the treatment group.
Fluorescence-Activated Cell Sorting Analysis
The effect of 5-aza-CdR on cell cycle distribution was determined
by flow cytometry after staining the cells with propidium iodide.
Briefly, control and 5-aza-CdR–treated (5 μM for 7 days) MCF-7
and ZR-75-1 cells were trypsinized and washed with phosphate-
buffered saline (PBS), and fixed with chilled 70% ethanol. The fixed
cells were then centrifuged and washed with PBS. The cells were
then treated with 1 U of DNase-free RNase to the cell suspension
(106 cells in 1 ml), and incubated for 30 minutes at 37°C. Fifty mi-
croliters of 1 mg/ml propidium iodide was added directly to the cell
suspension, and flow cytometry analysis was performed on a flow cy-
tometer (FACS Calibur; BD Biosciences, Ontario, Canada). Results
were analyzed further using the WinMDI software (version 2.8;
Scripps Research Institute, La Jolla, CA).
Boyden Chamber Matrigel Invasion Assay
Cells’ invasive capacity was determined using a two-compartment
Boyden chamber Matrigel invasion assay (Transwell; Costar Corning
Corporation, Burlington, MA) as described previously [21]. The
8-μm-pore polycarbonate filters were coated with basement mem-
brane Matrigel (50 μg/filter). A total of 5 × 104 cells treated with
or without 5-aza-CdR (1 and 5 μM) in 0.1 ml of medium were
added to the upper chamber and placed on top of a lower chamber
prefilled with 0.8 ml of serum-free medium supplemented with
25 μg/ml fibronectin (Sigma Aldrich) and then incubated at 37°C
for 24 hours. After incubation, the medium was removed, and the
polycarbonate filters with invaded cells were fixed in 2% paraformal-
dehyde, 0.5% glutaraldehyde (Sigma Aldrich) in 0.1 M phosphate
buffer, pH 7.4, at room temperature for 30 minutes. They were then
stained with 1.5% toluidine blue, washed, and mounted onto glass
slides. The number of cells invaded was examined under a light mi-
croscope. Ten fields under a magnification of ×400 were randomly
selected, and the mean number of cells invading was calculated.
Cell Wounding Assay
Confluent MCF-7 monolayer was grown in six-well plates as de-
scribed above with 2% fetal bovine serum. The cell monolayer was
mechanically wounded in the center of each well with a sterile 200-μl
pipette tip and maintained in the presence or absence of 5-aza-CdR
(1 and 5 μM) for 48 hours where the culture medium was changed
every 24 hours. Cells were then washed three times to get rid of the
detached cells and debris. Wound healing was monitored at differ-
ent time points with an inverted bright field microscopy under the
4× objective. Only cell-free area was selected, measured, and quanti-
fied using the Image Pro-Plus software (Media Cybernetics, Inc.,
Bethesda, MD) and calculated as percentage wound healing using
the equation: %wound healing = [1 − (wound area at Tx hours/wound
area at T0)], where the Tx is the respective time point and T0 is the
time immediately after wounding.
Reverse Transcriptase–Polymerase Chain Reaction Analysis
Total cellular RNA from control and 5-aza-CdR–treated MCF-7
and ZR-75-1 cells were extracted using TRIzol (Invitrogen Life
Technologies) according to the manufacturer’s protocol. Two micro-
grams of total RNA was used for reverse transcription and amplifica-
tion. The primers used for reverse transcription–polymerase chain
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reaction (RT-PCR) were designed so that there is an intron between
the amplified regions to recognize any DNA contamination. Two sets
of different RT-PCR primers were used in the present study; their
sequence and annealing temperature are given in Table 1. The reac-
tions were carried out using standard protocols. The DNA was am-
plified under the following conditions: 95°C for 5 minutes, 30 cycles
at 95°C for 30 seconds, annealing temperature of the respective
primer for 30 seconds as given in Table 1, and at 72°C for 30 sec-
onds, and the final extension at 72°C for 5 minutes. Different num-
bers of cycles were used to ensure linearity of amplification. The gels
were quantified by using the Scion Software (Scion Corporation,
Frederick, MD) for the densitometry.
Sodium Bisulfite Sequencing
Genomic DNA was extracted from control and 5-aza-CdR–treated
(5 μM for 7 days) MCF-7 cells using DNazol (Invitrogen Life Tech-
nologies) following the manufacturer’s instructions. Sodium bisulfite
treatment of the genomic DNA was performed as described previously
[21,22]. Two sets of primers were designed to amplify the modified
DNA fragment within the uPA promoter region with outer primers
(5′-GTAAGGGGGTTTGAGGTAGT-3′ and 5′-ATAACCAAACT-
CCCCAACTA-3′) and inner primers (5′-TTTAGGTAAGTTGG-
GGTTTAG-3′ and 5′-TCTCTCTCCTCTATAAACTC-3′) of the
uPA promoter sequence. The amplification reaction was performed
under the following conditions: 95°C for 5 minutes; 34 cycles at
95°C for 1 minute, at 51°C for 2.5 minutes, and at 72°C for 1 minute;
final extension at 72°C for 5 minutes. For CXCR4, the bisulfite DNA
was subjected to primary and nested PCR using two sets of primers
from the promoter and exon 1 region; outer primers (5′-TTATTTAT-
TTAGTAAGGATGGA-3′ and 5′-AATACCTCCAATATCCTAAC-
3′) and inner primers (5′-AAATGTTTTTGGGAGGTTTTG-3′
and 5′-CACTAATCCCCTCCATAATA-3′) at 95°C for 5 minutes;
34 cycles at 95°C for 30 seconds, at 50°C for 30 seconds, and at
72°C for 30 seconds; final extension at 72°C for 5 minutes. For SNCG
genomic bisulfite sequencing, first-step PCR was carried out using the
outer set of primers (5′-GGTTGAGTTAGTAGGAGTTTA-3′ and
5′-CCTACCATACCCCACTTACCC-3′,) and nested PCR was car-
ried out using the inner set of primers (5′-TATTTTGGAGGAAGGT-
GAGGTTG-3′ and 5′-CCACTTACCCACATACATAACC-3′) at
95°C for 5 minutes; 34 cycles at 95°C for 30 seconds, at 58°C for
30 seconds, and at 72°C for 30 seconds, and a final extension at
72°C for 5 minutes.
Finally, PCR products of the uPA, CXCR4, and SNCG were purified
by using QIAquick PCR purification kit (Qiagen Inc., Ontario, Canada)
and subcloned into pGEMT cloning vector (Promega, Madison, WI)
according to the manufacturer’s instruction, and plasmid DNA from
different bacterial clones was prepared and analyzed for DNA sequences
(Genome Centre, McGill University, Quebec, Canada). At least
10 clones for each gene were sequenced per treatment group.
In Vivo Tumor Growth in Breast Cancer Model
Six-week-old female Balb C nu/nu mice were obtained from
Charles River, Inc. (St. Constant, Quebec, Canada). Before inocula-
tion, MCF-7 cells were treated with 5 μM of 5-aza-CdR for 7 days
in regular growth media. Growth medium and drug was changed
every second day during treatment. On day 8, treated and untreated
MCF-7 cells were trypsinized and washed with Hank’s balanced
buffer; 2.5 × 106 cells were resuspended in 100 μl of saline with
20% Matrigel (Becton Dickinson Labware, Ontario, Canada). An
anaesthetic cocktail of ketamine (50 mg/kg), xylazine (5 mg/kg),
and acepromazine (1 mg/kg) was injected intramuscularly, and 2.5 ×
106 cells were inoculated using 30-gauge needles into the mammary
fat pad of anaesthetized mice. All experimental animals (eight ani-
mals in each group) were implanted with 0.25 mg of estradiol pellet
with 60-day release (Innovative Research of America, Sarasota, FL)
through subcutaneous route using a trocar. All the experimental ani-
mals were taken care of in accord with the McGill University Animal
Care Committee.
Both control and experimental animals were monitored at weekly
intervals for the development of tumors for 6 weeks. Tumor volume
was determined according to the formula: tumor volume = shorter
diameter2 × longer diameter / 2. Results were presented as the mean
of tumor volumes recorded from both groups. At the end of the study,
control and experimental animals were sacrificed; primary tumors were
removed and fixed in 10% buffered formalin and Bouin’s solution, re-
spectively. Before fixation, tumors were divided into two halves, one
half was fixed in formalin and embedded in paraffin for histologic anal-
yses by light microscopy. The other half was snap-frozen in liquid
nitrogen to analyze the expression of various genes by RT-PCR.
Immunohistochemical Analyses
Bouin’s solution-fixed tumor samples were processed for immuno-
histochemistry. The fixed tissues were embedded in paraffin. Paraffin-
embedded tumor samples were cut into 5-μm-thick sections; for
immunohistochemical analysis for uPA, CXCR4, and heparanase,
a prometastatic marker was carried out as using the avidin-biotin-
peroxidase complex technique. Briefly, the sections were deparaffin-
ized in xylene followed by rehydration through a series of ethanol
to water gradients. The sections were treated with 1% normal goat
Table 1. Different Sets of Primer Sequences and Annealing Temperatures Used for RT-PCR Analysis.
Genes Primer Sequence for RT-PCR Tm Value (°C)
Tumor suppressor gene
RASSF1A 5′-ACCTCTGTGGCGACTTCATCT-3′ 52
5′-AGGTGAACTTGCAATGCGC-3′
Involved in metastasis
uPA 5′-ACATTCACTGGTGCAACTGC-3′ 56
5′-CAAGCGTGTCAGCGCTGTAG-3′
SNCG 5′-CAAGAAGGGCTTCTCCATCGCCAAGG-3′ 60
5′-CCTCTTTCTCTTTGGATGCCACACCC-3′
HEPARANASE 5′-TTCGATCCCAAGAAGGAATCAAC-3′ 55
5′-GTAGTGATGCCATGTAACTGAATC-3′
CXCR4 5′-GGAGGGGATCAGTATATACA-3′ 55
5′-GAAGATGATGGAGTAGATGG-3′
CXCL12 5′-AGAGCCAACGTCAAGCATCT-3′ 55
5′-CGTCTTTGCCCTTTCATCTC-3′
Involved in angiogenesis
VEGF 5′-CCTGGTGGACATCTTCCAGGAGTA-3′ 58
5′-CTCACCGCCTCGGCTTGTCACA-3′
Involved in cell cycle
TGF-β 5′-GTACCTGAACCCGTGTTGCT-3′ 54
5′-TACAGCTGCCGCACGCAGCA-3′
p21WAF1/Cip1 5′-CTCAGAGGAGGCGCCATG-3′ 55
5′-GGGCGGATTAGGGCTTCC-3′
CYCLIN D1 5′-TGGATGCTGGAGGTCTGCGAGGAA-3′ 60
5′-GGCTTCGATCTGCTCCTGGCAGGC-3′
CYCLIN E1 5′-AGTTCTCGGCTCGCTCCAGGAAGA-3
5′-TCTTGTGTCGCCATAATCCGGTCA-3′
56
Involved in apoptosis
BAX 5′-ATGGACGGCTCCGGGGAG-3′ 51
5′-TGGAAGAAGATGGGCTGA-3′
GAPDH 5′-CCCTTCATTGACCTCAACTACATGGT-3′ 56
3′-GAGGGGCCATCCACAGTCTTCTG-5′
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serum (Vector Laboratories Inc., Burlingame, CA), to block the non-
specific binding, for 30 minutes at room temperature before incuba-
tion with the primary antibodies: monoclonal antibody against uPA
(American Diagnostics Inc., Stamford, CT) and monoclonal anti-
bodies against CXCR4 and heparanase (Santa Cruz Biotechnologies,
Santa Cruz, CA); primary anti-uPA, CXCR4, and heparanase anti-
bodies were used at 1:50 dilution overnight at 4°C under the condi-
tions described by manufacturer. Throughout the experiment, after
each step, all sections were washed three times, 10 minutes each,
with Tris buffer (pH 7.6). Biotinylated goat anti–mouse IgG (Vector
Laboratories Inc., Burlingame, CA) and HRP donkey anti–goat or
goat anti–mouse IgG (Bio-Rad Laboratories Ltd., Ontario, Canada)
were used as the secondary antibodies at a dilution of 1:200 for 1 hour
at room temperature. The sections for uPA staining were treated with
vectastain ABC-AP kit (Vector Laboratories Inc., Burlingame, CA).
The immunoreaction was visualized with Fast Red TR/Naphthol
AS-MX phosphate (Sigma Aldrich) containing 1 mM levamisole
(uPA) and DAB HRP substrate kit (Vector Laboratories Inc., Ontario,
Canada) for CXCR4 and heparanase for 5 to 10 minutes. The sections
were counterstained with hematoxylin (Fisher Scientific, Ltd., Ontario,
Canada) and mounted with Kaiser’s glycerol jelly or paramount. For all
negative controls included in the study, the primary antibody was sub-
stituted with PBS. Ten random fields were selected from the previously
coded slides and manually scored as arbitrary units for the expression
level of these genes [35].
Statistical Analysis
Results were analyzed as the mean ± SEM, and comparisons of the
experimental data were analyzed by a two-tailed independent-sample
Student’s t test at 0.05 level of significance.
Results
Effect of 5-Aza-CdR on Cell Proliferation, Cell Cycle,
and Migration
To verify that 5-aza-CdR exhibits the previously described effects
on cell growth in vitro of the noninvasive breast cancer cell lines
MCF-7 and ZR-75-1, we measured the effects of two doses of
5-aza-CdR on cell viability, cell doubling time, and cell cycle ki-
netics [36]. The results presented in Figure 1, A and B, show that
5-aza-CdR is increasing cell doubling time significantly at 1 and 5 μM
doses. A FACS analysis of cell cycle distribution on control and 5-aza-
CdR–treated cells (5 μM for 7 days) reveals a significant increase in
the proportion of cells in the G2 phase, with a concomitant decline in
S phase (Figure 1 C ) in the treatment groups of both cell lines. Our re-
sults showed that 5-aza-CdR decreases cell proliferation under the con-
ditions used in our study.
To determine whether 5-aza-CdR treatment affects the expression of
uPA, a key protease involved in tumor cell invasion, MCF-7 and ZR-
75-1 cells were treated with different doses of the 5-aza-CdR. Results
from these studies showed a significant (P < .05) dose-dependent in-
crease in the uPA expression at 1.0 and 5.0 μM concentrations of
5-aza-CdR (Figure 1 D). At these doses, more than 95% of tumor
cells were viable. This change in the expression of uPA had a dose-
dependent increase in tumor cells’ invasive capacity as determined
by the Boyden chamber Matrigel invasion assay (Figure 1D). The ef-
fect of 5-aza-CdR on cell migration was analyzed using MCF-7 cells,
rather than ZR-75-1 cells that grow in patches. A significant (P < .05)
increase in wound healing (%) was observed in 5-aza-CdR–treated
(5 μM) MCF-7 cells compared with control cells at 32 and 48 hours
after wounding (Figure 1, E and F ). Healing at the lower dose of 5-aza-
CdR (1 μM) was also found to be significant (P < .05) compared with
control MCF-7 cells. For both, control and 5-aza-CdR–treated groups,
the rate of wound closure was highest at 24 and 32 hours after wound-
ing. Migration assay on ZR-75-1 cells was not feasible, because these
cells grow in patches and are unable to form a uniform monolayer.
Effect of 5-Aza-CdR on the Genes Involved in Invasion
and Metastasis
What is the mechanism by which 5-aza-CdR stimulates cell inva-
sion and migration? We tested the hypothesis that 5-aza-CdR induces
a battery of genes, which were previously reported to be involved in
cell invasion and metastasis, including uPA, SNCG, HEPARANASE,
CXCR4, and CXCL12. MCF-7 and ZR-75-1 cells were treated with
5 μM 5-aza-CdR for a duration of 7 days. At the end of the experi-
ment, total cellular RNA was isolated and analyzed for the expression
of mRNA levels of these genes as well as the tumor suppressor gene,
RASSF1A, which is hypermethylated in 42% to 65% of primary breast
tumors, including these cell lines [26]. We found that, as reported,
5-aza-CdR treatment upregulated the expression of the tumor suppres-
sor gene, RASSF1A, in both cell lines. However, in addition to the
tumor suppressor gene, a number of genes demonstrated to play a
causal role in metastasis were induced as well, namely uPA, SNCG,
HEPARANASE, the chemokine receptor CXCR4, the cytokine TGF-β,
and the angiogenesis factor VEGF (Figure 2). There is no significant dif-
ference in CXCL12 or CYCLIN D1 and CYCLIN E1mRNA expression
in control and 5-aza-CdR–treated groups of either cell lines. Thus, our
RT-PCR data confirm that 5-aza-CdR is responsible for the activation of
quiescent genes or upregulation of a panel of prometastatic genes that
are normally suppressed in these noninvasive cell lines concurrently with
its activation of tumor suppressor genes.
Effect of 5-Aza-CdR on the Methylation Status of the uPA,
CXCR4, and SNCG Gene Promoters
To test the hypothesis that the increase in mRNA expression of
these genes is due to concurrent demethylation in the promoter
and exon 1 region of these genes, we subjected genomic DNA from
treated and untreated cells to sodium bisulfite mapping of the indi-
cated regulatory regions of uPA, SNCG, and CXCR4 promoters
(Figure 3 A). Demethylation of specific CpG sites after 5-aza-CdR
treatment was noted for these three genes. The uPA promoter was
highly methylated (81.8%) in the MCF-7 control; significant de-
methylation occurs at an SP1-binding site and four CpG sites located
between TATA box and exon 1 as well as extensive demethylation of
exon 1. CXCR4 regulatory region (−260 to +150) was almost totally
demethylated by 5-aza-CdR (Figure 3 B). The CpG site numbers 2
to 14 and 16 on the SNCG promoter region are more prone to de-
methylation after 5-aza-CdR treatment, consistent with the possibil-
ity that demethylation of these sites may play an important role in
the induction of this gene (Figure 3 C ).
Effect of 5-Aza-CdR on In Vivo Tumor Growth
Following the in vitro data indicating that 5-aza-CdR induces a bat-
tery of genes involved in metastasis as well as tumor suppressor genes,
we tested whether 5-aza-CdR–treated cells will exhibit this dual re-
sponse; that is, reduced tumor growth and increased prometastasis
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gene expression in vivo. 5-Aza-CdR–treated (5 μM for 7 days in vitro)
MCF-7 cells and control cells were inoculated in the mammary fat pad
of female Balb C nu/nu mice in the presence of an estrogen pellet. As
depicted in Figure 4 A, 5-aza-CdR–treated MCF-7 cells showed a
reduced rate of increase in tumor volume compared with the control
group of animals inoculated with MCF-7 cells treated with vehicle
alone. Because 5-aza-CdR treatment was transient and the animals
were not further treated with 5-aza-CdR after inoculation, we con-
firmed by RT-PCR that the genes (uPA, HEPARANASE, CXCR4,
SNCG, and VEGF ) induced by 5-aza-CdR in vitro were still induced
in these tumors (Figure 4 B).
We then measured the levels of expression of uPA, CXCR4, and
HEPARANASE, which are key players in tumor invasion and metas-
tases, by immunohistochemistry in control tumors and tumors from
animals inoculated with cells treated with 5-aza-CdR. We found that
all tumors from the treatment group showed overexpression of uPA,
CXCR4, and HEPARANASE both in terms of intensity and density
compared with tumors from the control animals (Figure 5). Our data
showed that genes induced by 5-aza-CdR in vitro are not changed
after inoculating these cells in the in vivo model, both at the mRNA
and protein levels.
Discussion
Disruption in the DNA methylation machinery resulting in global
hypomethylation [37] and regional hypermethylation [1] is well
documented in most cancers. However, most of the focus of atten-
tion in the field has been on hypermethylation and silencing of
tumor suppressor genes, leading to a number of clinical trials with
the DNA methylation inhibitor 5-aza-CdR [7,38]. This approach is
effective in inhibiting tumor growth, and it has shown promising
results in the treatment of myelodysplastic syndromes [38,39]. How-
ever, this approach overlooks the other side of the methylation tale in
cancer: global hypomethylation. If global hypomethylation plays a
causal role in the cancer, then agents which globally inhibit DNA
methylation, such as 5-aza-CdR, might have undesirable effects after
their use, which can potentially affect cancer progression [24]. An
important requirement in developing effective cancer therapeutics
is to block not only primary tumor growth but also tumor metastases
to distant organs, which is the major cause of cancer-associated mor-
bidity and mortality [40]. We have previously shown that DNA
methylation plays divergent roles in growth and metastasis in breast
cancer cells [25]. Recent data implicating hypomethylation in the
activation of certain prometastatic genes, such as uPA [22,23,25],
in invasive breast cancer prompted us to test the hypothesis that in-
hibitors of DNA methylation would promote the transition of non-
metastatic breast cancer cells into metastatic cancer by inducing a
panel of genes required for metastasis.
Our study tested the hypothesis that hypomethylation coregulates
a panel of genes involved in metastasis by a common activation
mechanism rather than a specific gene. If this hypothesis is true, it
has obvious important therapeutic implications. First, it draws atten-
tion to the potential danger in using demethylating agents in antican-
cer therapy because of their potential effects on activating a large
number of quiescent genes including genes involved in promoting
tumor metastases. Nevertheless, it puts forward the opportunity of
an opposite approach, namely, inhibition of hypomethylation by hy-
permethylation therapy [23]. Such therapy might provide a unique
opportunity for knocking out a whole panel of genes involved in
metastasis, thus increasing the chances for successfully blocking me-
tastasis in contrast to therapies, which target one protein at a time.
Redundancy in activity of these proteins might require a therapeu-
tic approach that coordinately targets a panel of genes involved in
tumor progression.
Our data support this hypothesis. First, we show that 5-aza-CdR
concurrently activates the tumor suppressor gene, RASSF1A, and a
panel of prometastatic genes (Figure 2). We also show that the mech-
anism of action of 5-aza-CdR on three selected genes, namely, uPA,
CXCR4, and SNCG, involves demethylation of their regulatory re-
gions. These genes, uPA, CXCR4, and SNCG, were previously shown
to be regulated by hypomethylation in other systems; however, here
we show their simultaneous activation in the same noninvasive breast
cancer cells with 5-aza-CdR [22,23,29,30,41,42].
Recently, a study has shown that overexpression of the metastatic
gene, HEPARANASE, in MDA-MB-435 human breast carcinoma
and rat C6 glioma cells resulted in a three- to six-fold increase in
VEGF mRNA levels, which is mediated by the activation of Src fam-
ily members [43]. In the present study, we also found the upregula-
tion of HEPARANASE accompanied by the overexpression of VEGF
mRNA level in 5-aza-CdR–treated MCF-7 cells. However, it is un-
clear whether this increase in VEGF expression is due to epigenetic
regulation or is an outcome of HEPARANASE expression. It has been
Figure 1. Effect of 5-aza-CdR treatment on the proliferation, invasion, and migration of noninvasive cell lines. Noninvasive breast cancer
cells, MCF-7 and ZR-75-1, were seeded at the same density and subjected to two different doses of 5-aza-CdR or with vehicle control
alone (CTL) in a six-well plate, and growth curve analysis was carried out to determine the effect of 5-aza-CdR on the proliferation rate. At
each time point, cells were trypsinized and counted as described in the Materials and Methods section (A and B). All data presented are
expressed as mean ± SEM of quadruplicate wells for each time point. Similar results were obtained in two independent experiments.
Cell cycle distribution analysis was carried out by FACS for control and 5-aza-CdR–treated MCF-7 and ZR-75-1 cells (5 μM for 7 days)
after staining the cells with propidium iodide as described in the Materials and Methods section. Data were analyzed by WinMDI version
2.8 and plotted (C). Data are presented as mean of % events from three independent experiments by 100% stacked column graph for
control and experimental groups. Expression of uPA, a protease involved in invasion, was analyzed by RT-PCR in MCF-7 and ZR-75-1
cells treated with different doses of 5-aza-CdR (D). Data were presented for control and experimental groups as mean ± SEM values
from two independent experiments. The invasive capacity of MCF-7 and ZR-75-1 cells treated with different doses of 5-aza-CdR was
determined using a Boyden chamber Matrigel invasion assay. The bar diagram represents the mean ± SEM as described in the Mate-
rials and Methods section. Wound healing migration assay was carried out on MCF-7 cells in the absence and presence of 5-aza-CdR (1
and 5 μM) in the culture medium with 2% fetal bovine serum as depicted in panels E and F. Cells were seeded at the same density and
grown as monolayer and wounded as discussed in the Materials and Methods section. %Wound healing was recorded at different time
points, and percentage of wound healing with respect to T0 was calculated using the described equation. Similar results were obtained
from two different experiments. All data were presented as mean ± SEM of duplicate values from control and experimental groups from
two independent experiments. Significant difference from the control is represented by an asterisk (*P < .05).
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demonstrated that exogenous expression of SNCG in breast cancer
cells (MDA-MB-435) led to a significant increase in cell motility
and invasiveness in cell culture and to a profound augmentation of
metastasis in nude mice [17]. The other genes of interest were CXCR4
and CXCL12; CXCR4 is a Gi protein–coupled receptor for the ligand
CXCL12 and plays an important role in breast cancer metastasis. Che-
mokine receptors, such as CXCR4 and CXCR7, play an important
role in cell migration and metastasis [42]. Recently, it has been shown
that elevated secretion of CCL2 by bone marrow endothelial cells re-
cruits prostate cancer epithelial cells to the bone microenvironment
Figure 3. Treatment with 5-aza-CdR causes demethylation of the promoter region of the uPA, CXCR4, and SNCG genes. MCF-7 cells
were subjected to 5-aza-CdR treatment (5 μM) for 7 days, at which point genomic DNA was isolated with DNazol and subjected to
bisulfite treatment as described in the Materials and Methods section. Genomic bisulfite–treated DNA was used for first PCR and nested
PCR reactions to amplify uPA, CXCR4, and SNCG genes’ 5′ regulatory regions and the first exon, followed by cloning in pGEMT vector.
Ten clones for each gene were picked from control and treatment groups. A physical map of the uPA (A), CXCR4 (B), and SNCG (C)
promoters is presented. Demethylated CpG site (empty circle) and methylated CpG site (filled circle). Beneath the clones is the bar
diagram showing percent unmethylation for each CpG site present within the amplified region.
Figure 2. Treatment of MCF-7 and ZR-75-1 cells with 5-aza-CdR activates tumor suppressor and prometastatic genes. MCF-7 and ZR-75-1
cells were treated with 5 μM 5-aza-CdR for 7 days, and at the end of the experiment, total cellular RNA was isolated with TRIzol. RNA from
control and treatment groups were analyzed for the expression of genes involved in invasion, metastasis, cell cycle regulation, angiogen-
esis, and apoptosis by RT-PCR. The expression of tumor suppressor gene, RASSF1A, was also analyzed. Changes in the mRNA expression
of the respective genes were determined by plotting the relative ratio against GAPDH of at least two different experiments, where white
bars represent controls and solid black bars represent 5-aza-CdR–treated groups. Significant difference from the control is represented by
an asterisk (*P < .05).
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[44]. In parallel, Kollmer et al. [45] has also shown that the chemokine
CXCL12 promotes solid metastatic tumor growth by pro-proliferative
and antiapoptotic actions in an angiogenesis-dependent manner.
Another ubiquitous cytokine TGF-β that is found to be upregu-
lated in our findings is involved in bone metastasis and inhibits
growth of normal epithelia and early-stage tumors but stimulates in-
vasion and metastasis of aggressive tumors [46]. Although in some
cases, the loss of growth inhibition by TGF-β can arise because of
mutational inactivation of the TGF-β receptors and SMAD signaling
molecule [47] or might be due to hypermethylation. The effect of
TGF-β on tumor growth is biphasic: carcinogenesis and early tumor
growth are suppressed by TGF-β, whereas this growth factor appar-
ently accelerates tumor progression in more advanced aggressive tu-
mors. Thus, it presents another example of divergent effects on
growth and metastasis in breast cancer progression. Most impor-
tantly, the high level of uPA in serum and extracts from the primary
tumors are associated with poor prognosis and overall survival. In
fact, uPA has been proven to be an important marker of the meta-
static potential in human cancers [23,27,48,49]. uPA is required to
generate the active zymogen plasmin necessary for the degradation
of extracellular matrix and to promote metastasis, and there are re-
ports where tumor metastasis was selectively reduced up to more
than seven-fold in uPA-deficient mice [50].
The uPA promoter region we have evaluated has many transcrip-
tion factor-binding sites, namely, ETS-1, AP-2, and SP-1, which
may play important roles in the regulation of uPA expression. In pre-
vious studies, using mobility shift assay, we have shown that the tran-
scription factor Ets-1 is involved in inducing uPA gene expression.
This transcription factor-binding site coincides with methylation
sites and is a candidate site that can be affected by DNA meth-
ylation [21]. In addition, uPA gene activation by 5-aza-CdR can
also occur indirectly by additional transcription factors or by TGF-β
which is known to regulate the production of uPA through the
stabilization of uPA mRNA and through the SMAD-4 signaling path-
way [51]. Furthermore, integrin-linked kinase, which is critical for
TGF-β1–stimulated tumor cell-invasiveness, might also serve as
Figure 3. (continued)
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a key signaling mediator of TGF-β regulation of the uPA/plasminogen
activator inhibitor-1 system.
The main question with relevance to the clinical situation was
whether 5-aza-CdR–treated breast cancer cells would metastasize
in vivo. We opted to treat the cells in vitro and then inoculate them
in vivo rather than treat systematically with 5-aza-CdR to measure
the direct effect of the DNA-demethylating agent on the cancer cell
itself without the confounding factors of the systemic effects of 5-aza-
CdR and its potential effects on the stroma. In addition, this para-
digm allows us to evaluate the long-term effects of transient 5-aza-
CdR treatment. Because the action of 5-aza-CdR results in a stable
change in the state of modification of the DNA molecule per se, we
predicted that the early effects of 5-aza-CdR treatment would linger
for the entire period of time of tumor growth in vivo well after the 5-
aza-CdR was washed away. Our data show that while 5-aza-CdR de-
creases tumor growth in vivo, it also upregulates the expression of
many prometastatic genes in the noninvasive breast cancer cells
in vitro and in the primary tumors in vivo, which may result in me-
tastases at the distant organ sites of these animals over time. The ef-
fects of 5-aza-CdR last long after the 5-aza-CdR is withdrawn,
supporting the hypothesis that the effects of 5-aza-CdR are mediated
through reprogramming of gene expression, which is consistent with
a mechanism involving the change in DNA methylation rather than
in an immediate nonspecific effect of the drug which is independent
of DNA methylation. Because of the nonmetastatic behavior of
MCF-7 cells, we were unable to conclusively demonstrate the ability
of 5-aza-CdR to promote tumor metastases in this short-term in vivo
model of breast cancer.
Altering the DNA methylation machinery is a potentially powerful
approach to cancer therapy [52]. However, it is crucial to gain full
understanding of the mechanisms involved in these two processes,
namely, hypermethylation and demethylation, to properly use these
drugs targeting the DNA methylation machinery in anticancer ther-
apy. Because metastases is one of the most serious facets of cancer,
Figure 3. (continued)
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Figure 4. 5-Aza-CdR suppresses tumor growth and upregulates the expression of prometastatic, angiogenetic, and tumor suppressor
genes in primary tumor. Female Balb C nu/nu mice were inoculated with either control MCF-7 cells or MCF-7 cells treated with 5 μM
5-aza-CdR for 7 days in the mammary fat pad region in the presence of 0.25 mg of estradiol pellet for a 60-day release. Tumors
were measured weekly, and tumor volume was determined as described in the Materials and Methods section. Result represents
the mean ± SEM of eight animals in each group. Significant difference from the control is represented by an asterisk (*P < .05) (A).
At the termination of the in vivo experiment (week 6), primary tumors were excised and snap-frozen. Total cellular RNA was isolated
from these tumors using TRIzol and was analyzed by RT-PCR for the expression of genes responsible for invasion and metastases (uPA,
HEPARANASE, CXCR4, CXCL12, and SNCG) and angiogenesis (VEGF) and for the tumor suppressor gene (RASSF1A) as shown (repre-
sentative three tumor samples from each group) in panel B. The bar diagram represents the mean ± SEM of tumors from three animals
in each group (white bars represent mean ± SEM of controls and solid black bars represent mean ± SEM of the 5-aza-CdR–treated
group). Significant difference from the control is represented by an asterisk (*P < .05).
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and it plays a critical role in mortality from cancer, high vigilance is
warranted when using demethylating agents in cancer therapy. Our
challenge is to design agents that target the growth-promoting effect
of DNA methyltransferases but are devoid of the hypomethylation
action of critical prometastatic genes.
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